Treatment Options for Glaucoma Symptoms
Patients experiencing symptoms of glaucoma such as loss of peripheral vision, severe eye pain, or blurred vision require immediate ophthalmological evaluation, as these may indicate acute angle-closure glaucoma which is an ophthalmological emergency requiring same-day treatment to prevent permanent vision loss.
Types of Glaucoma and Their Presentations
Acute Angle-Closure Glaucoma
- Symptoms: Severe eye pain, blurred vision, halos around lights, headache, nausea/vomiting, eye redness, and a mid-dilated pupil 1
- Signs: Conjunctival hyperemia, corneal edema, shallow anterior chamber, and extremely elevated intraocular pressure (>40-50 mmHg) 1
- Risk factors: Hyperopia, shallow anterior chamber depth, short axial length, thick crystalline lens, steep corneal curvature, Asian descent, older age, female gender, family history 1
Primary Open-Angle Glaucoma
- Symptoms: Often asymptomatic until advanced stages when peripheral vision loss becomes noticeable
- Signs: Increased cup-to-disc ratio (>0.6), characteristic peripheral visual field defects 2
- Risk factors: Older age, elevated intraocular pressure, African American ethnicity, family history, high myopia 3
Treatment Algorithm
For Acute Angle-Closure Glaucoma (Emergency)
Immediate referral: Same-day ophthalmology evaluation is essential 1
Medical therapy to rapidly lower IOP:
Definitive treatment:
- Laser peripheral iridotomy: Creates an opening in the iris to allow aqueous humor flow
- Surgical iridectomy: If laser treatment is not possible
- Evaluation of the fellow eye: Essential as it is also at high risk for developing acute angle closure 1
For Primary Open-Angle Glaucoma
Medical therapy (first-line treatment):
- Prostaglandin analogs: First-line agents that increase uveoscleral outflow
- Beta-blockers: Timolol 0.25-0.5% twice daily to reduce aqueous production 5
- Alpha-2 agonists: Reduce aqueous production and increase uveoscleral outflow
- Carbonic anhydrase inhibitors: Acetazolamide 250 mg to 1 g daily in divided doses 4
Laser therapy (if medical therapy is insufficient):
- Selective laser trabeculoplasty (SLT): Improves trabecular meshwork outflow
- Argon laser trabeculoplasty (ALT): Alternative to SLT
Surgical interventions (for refractory cases):
- Trabeculectomy: Creates a new drainage pathway
- Glaucoma drainage devices: Tube shunts to divert aqueous humor
- Minimally invasive glaucoma surgery (MIGS): Newer procedures with faster recovery
Follow-up Recommendations
Follow-up intervals should be based on target IOP achievement and disease progression 6:
- Target IOP achieved, no progression: Every 6 months (or 12 months if stable >6 months)
- Target IOP not achieved or progression present: Every 1-2 months
- Target IOP achieved but progression continues: Every 1-2 months
Important Considerations
Visual function impact: Newly diagnosed glaucoma patients often report difficulty with bright lights and light/dark adaptation, with approximately half expressing worry about potential blindness 7
Medication precautions:
Quality of life considerations: Glaucoma can significantly impact daily activities such as driving (particularly at night) and increase fall risk 2
Medication compliance: Essential for preventing disease progression and preserving vision
Potential Pitfalls
Misdiagnosis: Acute angle-closure glaucoma can be misdiagnosed as migraine or cluster headache 1
Medication triggers: Certain medications can precipitate acute angle closure in susceptible individuals, including anticholinergics, adrenergic agents, sulfonamides, and some over-the-counter cold medications 1
Delayed treatment: Without prompt intervention for acute angle-closure glaucoma, permanent vision loss can develop rapidly, with 18% of eyes becoming blind following an acute attack 1
Underestimating severity: Glaucoma is the second most common cause of permanent blindness in the United States and the most common cause among African Americans 8